Industry News

TapImmune Inc., a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer& metastatic disease, today announced its President and Chief Operating Officer, Dr. John Bonfiglio, will be a speaker and deliver a corporate presentation at the BioNetwork Partnering Summit on Wednesday, October 5 at 4:35 PM PT."/>
TapImmune President Dr. John Bonfiglio to Present at BioNetwork Partnering Summit on October 5, 2016
Fate Therapeutics, Inc., a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S."/>
Fate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions
Collegium Pharmaceutical, Inc. announced today that it has submitted a Supplemental New Drug Application to the U.S. Food& Drug Administration to enhance the label for Xtampza ® ER, an abuse-deterrent, extended-release opioid, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.. The sNDA includes comparative oral pharmacokinetic data..."/>
Collegium Submits Supplemental New Drug Submission to FDA for Xtampza® ER
Abeona Therapeutics Inc.. ABO-102 delivers first-in-man AAV-based gene therapy administered by single intravenous injection to treat CNS and peripheral manifestations of Sanfilippo syndrome type A Data Safety Monitoring Board approves ABO-102 dose escalation for the high-dose cohort. Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare..."/>
Abeona Therapeutics Announces Data Safety Monitoring Board Approves ABO-102 Dose Escalation for Second Cohort in Phase 1/2 Clinical Trial for Sanfilippo Syndrome Type A
AstraZeneca today announced new data demonstrating that respiratory syncytial virus hospitalization rates increased significantly during the 2014-2015 RSV season among US infants 1 RSV is a contagious, seasonal respiratory virus that can lead to a serious lung infection and hospitalization in high-risk..."/>
New Study Shows Increases in RSV Hospitalization among High-Risk Preterm Infants
BioDelivery Sciences International, Inc. announced additions to its Board of Directors. Timothy C. Tyson will join the BDSI Board of Directors as an independent member, and Dr. Mark A. Sirgo, BDSI's President and Chief Executive Officer and board member, will, in addition to his current positions, assume the role of Vice Chairman."/>
BioDelivery Sciences Announces Additions to its Board of Directors
Intellia Therapeutics, Inc., a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard, M.D., will participate in a panel discussion and present a company overview at the Jefferies Gene Editing/Therapy Summit on Tuesday, October 11, 2016.. Details of the presentation are as follows:. Jefferies Gene Editing/Therapy Summit Date:..."/>
Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit
Natus Medical Incorporated today announced that the Company will release its 2016 third quarter financial results before the market opens on Wednesday, October 19 th. Natus management will host an investment-community conference call the same day beginning at 8:00 a.m. Pacific Time to discuss those results and to answer questions.. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domestic..."/>
Natus Medical to Hold 2016 Third Quarter Financial Results Conference Call on October 19th
ZIOPHARM Oncology, Inc. today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies Gene Editing/Therapy Summit on Tuesday, October 11, 2016 at 2:40 p.m. ET in New York City.. ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and..."/>
ZIOPHARM to Present at the Jefferies Gene Editing/Therapy Summit
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’ s disease, other central nervous system diseases, pain and various types of cancer, today announced a collaboration with Ariana Pharma to use Ariana’ s proprietary KEM ® patient stratification technology to potentially accelerate ANAVEX 2-73’..."/>
Anavex Life Sciences and Ariana Pharma Collaborate to Accelerate Timelines and Improve Efficiency of Alzheimer’s and Parkinson’s Clinical Development Programs
CytoSorbents Corporation, a therapeutic device company commercializing its CytoSorb ® blood purification cartridge to control deadly inflammation in critically-ill and cardiac surgery patients, announced positive top-line safety data from its recently completed randomized, controlled REFRESH I cardiac surgery feasibility and safety trial. Following a detailed review of all reported adverse events in a total of 46..."/>
CytoSorbents Announces Positive Top-line Safety Data from REFRESH I Cardiac Surgery Trial
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that vBloc ® Neurometabolic Therapy is now available to U.S. veterans at U.S. Department of Veterans Affairs medical facilities. This is made possible through the previously-announced EnteroMedics partnership with Academy Medical, LLC, a certified..."/>
EnteroMedics Announces Partner's National VA Contract Includes vBloc® Therapy for the Treatment of Obesity
Lexicon Pharmaceuticals, Inc. today announced that it has entered into an agreement to buy out its remaining obligations under its clinical development financing arrangement with Symphony Icon Holdings LLC upon regulatory approval in the United States for the marketing and sale of telotristat ethyl. "In light of progress in the process of regulatory review of telotristat ethyl for carcinoid syndrome, we felt this would be an..."/>
Lexicon Pharmaceuticals Announces Agreement To Buy Out Remaining Obligations To Symphony Icon
Capricor Therapeutics, Inc., a clinical-stage biotechnology company developing biological therapies for cardiac and other serious medical conditions, today announced that its Phase II ALLSTAR clinical trial has completed patient enrollment. ALLSTAR is evaluating CAP-1002 in adults with cardiac dysfunction following a large heart attack. "As we and others have shown, CAP-1002 possesses the ability to promote therapeutic regeneration..."/>
Capricor Therapeutics Completes Enrollment in Phase II ALLSTAR Clinical Trial
NeuroMetrix, Inc. today announced a clinical study of Quell ® Wearable Pain Relief Technology™ in patients with chronic low back pain at the Brigham and Women’ s Hospital Pain Management Center. According to the Centers for Disease Control and Prevention, low back pain is the second most common cause of disability in US adults. The incidence of low back pain is as high as 12% of the general population at any given point in time, and nearly 25% of US adults report having..."/>
NeuroMetrix to Sponsor Study Assessing the Impact of Quell Technology on Chronic Low Back Pain
Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced a licensing agreement with AstraZeneca for global exclusive rights to AZD7986, a novel oral inhibitor of dipeptidyl peptidase I. DPP1 is an enzyme that catalyzes the activation of neutrophil serine proteases, which play a key role in pulmonary diseases such as non-cystic fibrosis bronchiectasis.."/>
Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor
Bionor Pharma ASA."/>
Bionor Pharma ASA - Disclosure of Shareholding
Porton Fine Chemicals, Ltd.,, a China-based contract development and manufacturing organization serving the global pharmaceutical industry is pleased to announce the launch of Porton USA's Technology Center based in Cranbury, NJ. This new venture will serve the US biopharmaceutical industry, offering drug development and cross-lifecycle research, development and manufacturing solutions from a strategic location convenient to East..."/>
Porton Launches its US Process Innovation Center
Innovus Pharmaceuticals, Inc., an emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men’ s and women's health and respiratory diseases, announced today the initiation of a pre-clinical and clinical program intended to evaluate the safety and efficacy of the combination of its supplement..."/>
Innovus Pharma Initiates Pre-Clinical and Clinical Program Evaluating the Safety and Efficacy of Vesele® with Sildenafil (Viagra®)

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology799 Articles
Consumer Discretionary715 Articles
Financials697 Articles
Industrials558 Articles
Health Care523 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at